

1 **Epidemiological and clinical features of SARS-CoV-2 Infection in children during**
2 **the outbreak of Omicron Variant in Shanghai, March 7-March 31, 2022**

3 Xiangshi Wang ^{1,†}, Hailing Chang ^{1,†}, He Tian ^{1,†}, Jingjing Li ¹, Zhongqiu Wei ¹, Yixue Wang
4 ², Aimei Xia¹, Yanling Ge¹, Jiali Wang ¹, Gongbao Liu ³, Jiehao Cai ¹, Jianshe Wang ¹, Qirong
5 Zhu ¹, Yanfeng Zhu ^{1,*}, Xiaowen Zhai ^{4,*}, Mei Zeng^{1,*}

6
7 ¹ Department of infectious diseases, Children's Hospital of Fudan University, National
8 Children's Medical Center

9 ² Department of intensive care medicine, Children's Hospital of Fudan University, National
10 Children's Medical Center

11 ³ Department of medical affairs, Children's Hospital of Fudan University, National Children's
12 Medical Center

13 ⁴ Department of Hematology, Children's Hospital of Fudan University, National Children's
14 Medical Center

15 † Xiangshi Wang, Hailing Chang and He Tian equally contributed to this paper.

16 * Address for correspondence:

17 Yanfeng Zhu, MD, PhD, Department of Infectious Diseases, Children's Hospital of Fudan
18 University, 399 Wanyuan Road, Shanghai 201102, China. E-mail: smilingyf@sina.com, Tel:
19 86-021-64931132 (office), 86-13916913420 (mobile).

20 Xiaowen Zhai, MD, PhD, Department of Hematology, Children's Hospital of Fudan University,
21 399 Wanyuan Road, Shanghai 201102, China. E-mail: zhaixiaowendy@163.com, Tel: 86-021-
22 64931902 (office), 86-18017590808(mobile).

23 Mei Zeng, MD, PhD, Department of Infectious Diseases, Children's Hospital of Fudan

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 University, 399 Wanyuan Road, Shanghai 201102, China. E-mail: zengmeigao@163.com, Tel:
25 86-021-64931132 (office), 86-15000284050 (mobile).

26

27 **Abstract**

28 **Objectives:** To understand the epidemiological and clinical characteristics of pediatric SARS-CoV-2
29 infection during the early stage of Omicron variant outbreak in Shanghai.

30 **Methods:** This study included local COVID-19 cases <18 years in Shanghai referred to the exclusively
31 designated hospital by the end of March 2022 since emergence of Omicron epidemic. Clinical data,
32 epidemiological exposure and COVID-19 vaccination status were collected. Relative risks (RR) were
33 calculated to assess the effect of vaccination on symptomatic infection and febrile disease.

34 **Results:** A total of 376 pediatric cases of COVID-19 (median age:6.0±4.2 years) were referred to the
35 designated hospital during the period of March 7-31, including 257 (68.4%) symptomatic cases and 119
36 (31.6%) asymptomatic cases. Of the 307 (81.6%) children;3 years eligible for COVID-19 vaccination,
37 110 (40.4%) received 2-dose vaccines and 16 (4.0%) received 1-dose vaccine. The median interval
38 between 2-dose vaccination and infection was 3.5 (IQR: 3, 4.5) months (16 days-7 months). Two-dose
39 COVID-19 vaccination reduced the risks of symptomatic infection and febrile disease by 35% (RR 0.65,
40 95% CI:0.53-0.79) and 33% (RR 0.64, 95% CI: 0.51-0.81). Two hundred and sixteen (83.4%)
41 symptomatic cases had fever (mean duration: 1.7±1.0.8 days), 104 (40.2%) had cough, 16.4% had
42 transient leukopenia; 307 (81.6%) had an epidemiological exposure in household (69.1%), school (21.8%)
43 and residential area (8.8%).

44 **Conclusion:** The surge of pediatric COVID-19 cases and multiple transmission model reflect wide
45 dissemination of Omicron variant in the community. Asymptomatic infection is common among

46 Omicron-infected children. COVID-19 vaccination can offer protection against symptomatic infection

47 and febrile disease.

48 **Introduction**

49 The COVID-19 pandemic has caused devastation to the world's population, resulting in more than
50 6 million deaths as of April 20, 2022. SARS-CoV-2 infection in most pediatric cases is mild as compared
51 to adults and the direct effect on child health is limited [1]. However, the indirect impacts on child medical
52 care, education and mental health are considerable owing to lockdown, disruption of essential health
53 service delivery, prolonged school closure and isolation [2,3]. The continuous genetic evolution of
54 SARS-CoV-2 virus results in the emergence of multiple new variants of concern (VOC), which are
55 associated with enhanced transmissibility or increased virulence and immune escape [4]. The Omicron
56 variant, which was detected in November 2021 and almost replaced Delta variant by the end of January
57 2022, has led to the fifth global wave of COVID-19 epidemic [5]. The significant rise of pediatric
58 infection was reported in the United States with children aged <18 years, representing 17.0%-19.0% of
59 all cases during the Omicron period since late December 2021 [6,7].

60 Pediatric COVID-19 cases only accounted for a small proportion of infection in the early stages of
61 the COVID-19 pandemic when many countries implemented non-pharmaceutical interventions and strict
62 containment measures [8-12]. However, the incidence rate of COVID-19 in children showed a rising
63 trend in the epidemic countries following suspension of lockdown and school reopening [12,13]. After
64 the large-scale epidemic in early 2020, China entered a normalization stage of prevention and control,
65 and massive COVID-19 vaccination campaign was launched nationwide in 2021. Inactivated SARS-
66 CoV-2 vaccine BBIBP-CorV (by Sinopharm) and CoronaVac (by Sinovac) were approved for emergency
67 use in children 3-17 years on June 2021 and COVID-19 vaccination program was initiated in pediatric
68 population since late July 2021 across China. From May 2020, local pediatric COVID-19 infection linked
69 to sporadic and cluster transmission were occasionally reported in China until the community outbreak

70 of Omicron variant appeared in Hong Kong Special Administrative Region since January 6, 2022 and
71 subsequently in Shanghai since early March 2020 [14]. Omicron variant spread rapidly in Shanghai by
72 the end of March and led to a surge of pediatric COVID-19 cases citywide. Here, we describe
73 epidemiological and clinical characteristic of Omicron variant infections in Shanghainese children during
74 the early stage of the outbreak.

75

76 **Subject and Method**

77 **Subject**

78 In this study, we included local COVID-19 cases <18 years of age who were notified in Shanghai
79 and admitted to the exclusively designated hospital in Shanghai by the end of March 2022. Prior to 28
80 March, all pediatric COVID-19 cases notified in Shanghai were referred to the designated hospital for
81 concentrating management and isolation. Since 28 March when a large number of cases were confirmed
82 by massive screening test, most of asymptomatic and mild pediatric cases aged 5-17 years were almost
83 sent to Fangcang shelter hospitals. All confirmed cases irrespective of symptoms are required for in-
84 hospital isolation and are discharged if the cycle threshold (Ct) value for the viral nucleic acid is great
85 than 35 on PCR test for the two consecutive respiratory samples taken 24-hour apart [15].

86 **Case definition and classification**

87 All COVID19 cases were laboratory-confirmed by the Shanghai CDC reference laboratory using
88 real-time RT-PCR commercial kit. The Ct value <40 was defined as a positive nucleic acid amplification
89 test. COVID-19 cases were classified as asymptomatic and symptomatic cases. Symptomatic cases were
90 classified as mild, moderate and severe cases. An asymptomatic case is defined as a person with a positive
91 nucleic acid test but without any clinical symptom of COVID-19. A confirmed symptomatic case is

92 defined as a person presenting clinical signs and symptoms of COVID-19. COVID-19 disease severity
93 classification is based on the WHO guidance [16]. Pneumonia was diagnosed based on clinical signs
94 (fever and/or cough accompanying with one of the following signs: moist rales on auscultation, difficulty
95 breathing/dyspnoea, fast breathing, chest indrawing), radiological findings compatible with pneumonia.

96 **Data collection**

97 Data were collected via a face-to-face interview with parents or teenagers and electronic medical
98 chart, including: demographic information, epidemiological exposure setting, COVID-19 vaccination
99 status on dose and date, clinical symptoms, laboratory findings and chest imaging if examined, treatment
100 and outcome. Informed consent from parents was not required by the ethics committee because all data
101 were de-identified and not involved in personal privacy.

102 **Statistical analysis**

103 Data was entered into Excel version 2016 (Microsoft, Redmond, Washington) for analysis and the
104 statistical analysis was performed using SPSS (IBM Statistic 23.0). Categorical variables are described
105 as absolute numbers and percentage. Continuous variables with normal distribution are expressed as
106 mean \pm standard deviation. Median (25% to 75% interquartile range (IQR) are used when the frequency
107 distributions were skewed. Differences between groups are compared using Mann-Whitney *U*-test and
108 Student's *t*-test as appropriate. A difference with $P < 0.05$ is considered to be statistically significant.
109 Relative risks (RR) were calculated using proportion of symptomatic infection and febrile cases by
110 vaccination status, with the referent group being ≥ 2 -dose vaccinees.

111 **Results**

112 **Demographic characteristics**

113 The first local pediatric case was notified on March 2022 and increased remarkably from 14 March
114 onwards (as shown in Figure 1). As of 31 March, a total of 376 pediatric cases of COVID-19 were

115 referred to the exclusively designated hospital. The ratio of male-to-female was 1.1 (206/170). The 376
116 cases were aged 11 days-17 years with the median age of 5.0 years (IQR: 2, 9) and the mean age of
117 6.0 ± 4.2 years: 28 (7.4%) cases in age group <1 year, 76 (20.2%) cases in age group 1-2 years, 94 (25.0%)
118 cases in age group 3-5 years, 134 (35.6%) cases in age group 6-11 years, and 44 (11.7%) cases in age
119 group ≥ 12 years.

120 **Epidemiological exposure**

121 Three hundred and seven (81.6%) cases had a clear history of exposure, of whom, 213 (69.1%)
122 had a close contact with confirmed adult cases in household, 67 (21.8%) had a clear contact with
123 confirmed child cases in school, and 27 (8.8%) had an epidemiological linkage to residential area
124 where cluster cases of COVID-19 were reported. As shown in Figure 2, the first child case acquired
125 infection in family, soon after, child cases linked to possible community transmission were found, who
126 had no clear exposure.

127 **Vaccination status**

128 A total of 126 had received at least one dose of an inactivated COVID-19 vaccine, accounting for
129 33.5% of the total 376 pediatric cases and 46.3% of the 272 pediatric cases aged ≥ 3 years eligible for
130 COVID-19 vaccination in China. Of the 272 vaccine-eligible children, 146 (53.6%) were unvaccinated,
131 110 (40.4%) had received 2 doses and 16 (4.0%) had received 1 dose. Among the 94 preschool children
132 aged 3-5 years, the proportions of 1 dose and 2 doses of COVID-19 vaccination were 3.2% (3/94) and
133 5.3% (5/94), respectively. Among the 178 school children aged 6-17 years, the proportions of 1 dose and
134 2 doses of COVID-19 vaccination were 7.3% (13/174) and 59.0% (105/174), respectively. Overall, the
135 interval between vaccination and breakthrough infection ranged from 16 days to 7 months (median: 3.5
136 (IQR: 3, 4.5) months).

137 As shown in table 1, 2-dose COVID-19 vaccination reduced the risk of symptomatic infection and
138 febrile disease by 35% (0.65, 95% CI: 0.53-0.79) and by 36% (RR 0.64, 95% CI: 0.51-0.81) in children
139 0-17 years, by 29% (RR 0.71, 95% CI: 0.57-0.88) and 29% (RR 0.71, 95% CI: 0.55-0.92) in children 3-
140 17 years eligible for COVID-19 vaccine. However, one-dose vaccination could not significantly decrease
141 the relative risks of symptomatic infection and febrile disease.

142 **Clinical manifestation and course**

143 Of the 376 cases, 257 (68.4%) presented symptoms and 119 (31.6%) had no symptoms before and
144 duration hospitalization. Of the 257 symptomatic cases, 216 (83.4%) experienced fever (axillary
145 temperature $>37.5^{\circ}\text{C}$) with a mean fever spike of $38.9 \pm 0.6^{\circ}\text{C}$ (range: $37.6-41^{\circ}\text{C}$) and a mean fever
146 duration of $1.7 \pm 1.0.8$ days (range: 0.5-4 days), 104 (40.2%) presented cough, 28 (10.8%) self-reported
147 sore throat, 13 (5.0%) self-reported stuffy nose, 6 (2.3%) had runny nose, 11 (4.2%) had nausea or
148 vomiting or diarrhea, 2 (0.8%) self-reported transient loss of taste and smell. No severe case was
149 diagnosed. Twenty five cases had chest CT performed due to fever $>38.5^{\circ}\text{C}$ lasting for 3 days or cough
150 worsening after admission or routine examination prior to the referral. The chest images showed patchy
151 infiltrates or ground-glass opacity in 4 cases and one of them was right lung lobar pneumonia caused by
152 *Mycoplasma pneumoniae*. Six (1.6%) cases had comorbidity including brain tumor, febrile seizure,
153 psychomotor retardation, hemophilia, Henoch-Schonlein purpura, and cardiac arrhythmia in each.

154 As shown in table 2, 22.8% (57/250) of unvaccinated cases were asymptomatic while 50.0%
155 (55/110) of 2-dose vaccinated cases were asymptomatic ($P=0.000$); 65.2% (163/250) of unvaccinated
156 cases were febrile while 41.8% (46/110) of 2-dose vaccinated cases were febrile ($P=0.000$).
157 Symptomatic infection was significantly frequently seen in the age group <3 years than in the age group
158 3-5 years ($P=0.003$) and 6-17 years ($P=0.000$). Fever was significantly frequently seen in the age group

159 3-5 years than in the age group <3 years (P=0.000) and 6-17 years (P=0.005).

160 Of the 225 case who had complete peripheral blood cell count tested, 37 (16.4%) had white blood
161 cell (WBC) count $<4 \times 10^9/L$, 173 (76.9%) had WBC count $4-9 \times 10^9/L$, 13 (5.8%) had WBC count $10-$
162 $14 \times 10^9/L$ and 2 (7.1%) had WBC count $\geq 15 \times 10^9/L$. The WBC count ranged from $1.9 \times 10^9/L$ to
163 $15.5 \times 10^9/L$. No thrombopenia was observed. Of the 187 cases who had peripheral blood C-reactive
164 protein (CRP) tested, 178 (95.2%) had CRP <8 mg/L, 8 (4.3%) had CRP >8 mg/L (range: 8.8-35.8 mg/L)
165 and 1 (0.5%) had CRP 56 mg/L who had co-infection with *mycoplasma pneumoniae* and developed
166 typical lobar pneumonia in right lung. Of the 196 cases who had serum biochemical markers and 8 (4.1%)
167 showed slightly elevated liver enzyme.

168 For symptomatic cases, Ibuprofen and or Chinese traditional medicines were prescribed depending
169 on the personalized condition and medication compliance. Only one case who had a clear diagnosis of
170 mycoplasma pneumonia was prescribed antibiotics. All cases were discharged when the Ct value of the
171 nucleic acid of SARS-CoV-2 virus reached >35 . The average duration of Ct value of the nucleic acid of
172 SARS-CoV-2 virus >35 since admission was 11.7 ± 3.7 days (range: 3-25 days; symptomatic verse
173 asymptomatic: 11.7 ± 3.6 verse 11.7 ± 3.9 , P=0.064).

174

175 **Discussion**

176 This study first presents the epidemiological and clinical profiles of Omicron variant infection in
177 localized children during the early phase of outbreak in Shanghai. As of 31 March 2022, all pediatric
178 COVID-19 cases were mild (68.4%) or asymptomatic (31.6%). However, a few of severe pediatric cases
179 were reported during the period of COVID-19 outbreak in Wuhan in early 2020 [17]. Moreover, the
180 proportion of asymptomatic cases was 2-time more than that seen in the Wuhan outbreak. We reason that

181 high coverage of COVID-19 vaccination among Shanghainese children is very likely to lower the risk of
182 severe Omicron infection-associated disease. The mass COVID-19 vaccination roll-out among children
183 3-17 years started between Mid-Aug 2021 and December 2021 in Shanghai and the estimated coverage
184 rate of 2-dose COVID-19 vaccination among children 3-17 years has exceeded 70% by the end of
185 March in 2022. In this case cohort 46.3% of children eligible for COVID-19 vaccination prior to 16 days
186 to 7 months (median: 3.5months). Observational studies from some countries with the high levels of
187 population immunity generated by natural infection or vaccine have shown receipt of two doses of
188 COVID-19 vaccines and a booster dose can offer protection against symptomatic and severe Omicron
189 infection in a short-term period of vaccination [4,18-22].

190 Current evidences consistently show a reduction in neutralizing antibody against Omicron in serum
191 of convalescent or vaccinated individuals, resulting in Omicron's immune escape potential against
192 vaccine- and infection-induced immunity [4,23]. However, two recent study based on real-world
193 observation among children showed the modest effectiveness for COVID-19 vaccine against Omicron
194 infection [25,26]. Based on our findings, receipt of 2-dose inactivated COVID-19 vaccine within 17 days
195 to 7 months after fully primary vaccination potentially reduced the risk of symptomatic Omicron
196 infection by 31% and febrile disease by 59% in children. We did not estimate vaccine protection against
197 severe infection because no severe COVID-19 cases were diagnosed. There is also evidence of waning
198 of vaccine effectiveness over time of the primary series against infection and symptomatic disease for
199 the studied vaccines. However, the vaccine effectiveness against Omicron infection and disease can be
200 restored and increase to > 40% to 80% within a short follow-up time after a third booster dose in studies
201 from five countries (United Kingdom, Denmark, Canada, South Africa, USA) [4]. Ten cases of
202 reinfection with Omicron variant were identified within 23 to 87 days of a previous Delta infection was

203 reported in the USA and most were pediatric cases [26]. Thus, eligible children and adolescents should
204 remain up to date with recommended COVID-19 vaccination in response to Omicron outbreak. So far, a
205 third booster dose of COVID-19 vaccine has been recommended for use in adults but not in children in
206 China. In light of the field findings, a booster dose should also be recommended for eligible children 3-
207 17 years.

208 We observed that school children aged 6-11 years comprised the most cases, followed by home-care
209 children <2 years and preschool children 3-5 year. The distribution of age groups in the early stage of
210 outbreak reflects the cluster transmission of COVID-19 centered in elementary school, kindergarten, and
211 household. Of note, age group 12-17 years accounted for the smallest proportion of pediatric cases,
212 among which, the high coverage rate of COVID-19 vaccination was as high as 95%. Based on the
213 epidemiological investigation, more than 80% children had a clear history of exposure, mostly occurring
214 in family (69.1%) and school (21.8%), occasionally in residential area (8.8%). The remaining 18.4% of
215 children had no clear contact with confirmed cases, reflecting small-scale community transmission had
216 already appeared prior to the large-scale outbreak since April. During the 2020 outbreak of COVID-19,
217 80%-90% of confirmed child cases were family cluster cases and community transmission was unusual
218 in China [17,27]. Rapid increases in pediatric COVID-19 cases and epidemiological unrelated cases also
219 suggest the occurrence of high community transmission of Omicron variant in Shanghai since the early
220 epidemic wave.

221 We observed most of localized pediatric cases (83.4%) of symptomatic Omicron infection
222 presenting fever. However, fever is less commonly seen in pediatric COVID-19 cases reported in China
223 (58%) and the USA (56%) during the first wave of pandemic in 2020 [10, 17]. Fever could be helpful for
224 early recognition and diagnosis of COVID-19 because parents always worry about the febrile child and

225 visit hospital for seeking medical care. The febrile course of Omicron infection is brief with a mean fever
226 duration of $1.7\pm 1.0.8$ days, significantly shorter than fever duration seen influenza (4 days) [28]. The
227 febrile duration is helpful to differentiate COVID-19 from influenza in children when the epidemics of
228 COVID-19 and influenza overlap.

229 The potential role in transmission for most asymptomatic and mild child cases should not be
230 neglected. A study showed that symptomatic and asymptomatic children can carry high quantities of live
231 SARS-CoV-2, creating a potential reservoir for transmission [29]. Vaccinees with mild or asymptomatic
232 Omicron infection shed infectious virus 6-9 days after onset or diagnosis, even after symptom resolution
233 [30]. In fact, asymptomatic infection in children was underestimated in the early stage of outbreak
234 because massive screening of COVID-19 cases had not been carried out before 28 March. After citywide
235 large-scale screening, notifiable asymptomatic cases accounted for 90% more or less in April.
236 Asymptomatic infection was much more common in vaccinated children than in unvaccinated children
237 (50% vs 22.8%). Vaccination can offer protection against symptomatic infection and febrile disease, on
238 the other hand, the role of asymptomatic children play in viral transmission is of attention during outbreak.
239 High prevalence of asymptomatic infection is likely a major factor in the widespread of the Omicron
240 variant among population.

241 In summary, COVID-19 is mild and subtle in Shanghainese children with the high level of vaccine-
242 induced immunity during the early stage of Omicron outbreak. COVID-19 vaccination can offer partial
243 protection against symptomatic COVID-19. Ongoing Omicron epidemic will increase the risk of
244 exposure among children with underlying medical conditions, who are usually unvaccinated, therefore,
245 severe COVID-19 infection is anticipated to be encountered in children. Non-pharmaceutical
246 interventions in combination with vaccination strategies are critical to prevent infection and severe

247 disease and to mitigate the impact of COVID-19 in pediatric population.

248 **Transparency declaration**

249 The authors have declared that there are no conflicts of interest in relation to this work. Disclosure forms
250 provided by the authors are available as Supplementary material.

251 *Funding*

252 This work was supported by the Science and Technology Commission of Shanghai Municipality (NO.
253 20JC141020002), the Key Development Program of Children's Hospital of Fudan University
254 (EK2022ZX05), the Three-Year Action Plan for Strengthening the Construction of Public Health System
255 in Shanghai (2020-2022) (GWV-3.2), and the Key Discipline Construction Plan from Shanghai
256 Municipal Health Commission (GWV-10.1-XK01). None of the funding organizations played any role
257 in the trial design, data collection, analysis of results, or writing of the manuscript.

258 **Author contributions**

259 Conceptualization: YZ, XZ, MZ; Methodology: XW, HC, HT, MZ; Software: XW, HC, HT; Validation:
260 JC; Formal Analysis: XW, HC, HT, YZ, MZ; Investigation: JL, ZW, YW, AX, YG, JW, GL, JC; Writing-
261 Original Draft: XW, HC, YZ, MZ; Writing-Review & Editing: XW, MZ; Visualization: JC, HC;
262 Supervision: YZ, GL, JW, QZ, XZ, MZ; Project Administration: XZ; Funding acquisition: XZ, MZ. All
263 authors approved the manuscript for publication.

264

265 **Reference**

266 1. World Health Organization. COVID-19 disease in children and adolescents: Scientific brief, 29
267 September 2021. Available from: [https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci_Brief-](https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci_Brief-Children_and_adolescents-2021.1)
268 [Children_and_adolescents-2021.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci_Brief-Children_and_adolescents-2021.1). [Accessed 18 April 2022].

- 269 2. World Health Organization. Pulse survey on continuity of essential health services during the
270 COVID-19 pandemic: interim report, 27 August 2020. Available from:
271 https://www.who.int/publications/i/item/WHO-2019-nCoV-EHS_continuity-survey-2020.1. [Accessed
272 18 April 2022].
- 273 3. Meherali S, Punjani N, Louie-Poon S, Abdul Rahim K, Das JK, Salam RA, et al. Mental Health of
274 Children and Adolescents Amidst COVID-19 and Past Pandemics: A Rapid Systematic. Review Int J
275 Environ Res Public Health 2021;18(7):3432. <https://doi.org/10.3390/ijerph18073432>
- 276 4. World Health Organization. Enhancing response to Omicron SARS-CoV-2 variant: Technical brief
277 and priority actions for Member States. Available at:
278 [https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-\(b.1.1.529\)-technical-brief-](https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states)
279 [and-priority-actions-for-member-states](https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states). [Accessed 22 April 2022].
- 280 5. World Health Organization. Weekly epidemiological update on COVID-19 - 1 March 2022. Available
281 from: [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-march-2022)
282 [march-2022](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-march-2022). [Accessed 22 April 2022].
- 283 6. Iuliano AD, Brunkard JM, Boehmer TK, Peterson E, Adjei S, Binder AM, et al. Trends in Disease
284 Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous
285 SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022. MMWR Morb
286 Mortal Wkly Rep 2022;71(4):146-52. <https://doi.org/10.15585/mmwr.mm7104e4>
- 287 7. American Academy of Pediatrics, Children's Hospital Association. Children and COVID-19:
288 State Data Report (Version3/31/22). Available from: [https://www.aap.org/en/pages/2019-novel-](https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/)
289 [coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/](https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/) [Accessed 22 April
290 2022].

- 291 8. World Health Organization (WHO). 2020. Report of the WHO-China joint mission on coronavirus
292 disease 2019 (covid-19). Available from: [https://www.who.int/publications/i/item/report-of-the-who-](https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19))
293 [china-joint-mission-on-coronavirus-disease-2019-\(covid-19\)](https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)). [Accessed 21 April 2022].
- 294 9. Choi SH, Kim HW, Kang JM, Kim DH, Cho EY. 2020. Epidemiology and clinical features of
295 coronavirus disease 2019 in children. *Clin Exp Pediatr* 63;(4):125-32.
296 <https://doi.org/10.3345/cep.2020.00535>
- 297 10. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February
298 12-April 2, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69(14):422-6.
299 <https://doi.org/10.15585/mmwr.mm6914e4>
- 300 11. Ladhani SN, Amin-Chowdhury Z, Davies HG, Aiano F, Hayden I, Lacy J, et al. COVID-19 in
301 children: analysis of the first pandemic peak in England. *Arch Dis Child* 2020;105(12):1180-5.
302 <https://doi.org/10.1136/archdischild-2020-320042>
- 303 12. Malcangi G, Inchingolo AD, Inchingolo AM, Piras F, Settanni V, Garofoli G, et al. COVID-19
304 Infection in Children and Infants: Current Status on Therapies and Vaccines. *Children (Basel)*.
305 2022;9(2):249. <https://doi.org/10.3390/children9020249>
- 306 13. Singhal T. The Emergence of Omicron: Challenging Times Are Here Again! *Indian J Pediatr*
307 2022;89(5):490-6. <https://doi.org/10.1007/s12098-022-04077-4>
- 308 14. Smith DJ, Hakim AJ, Leung GM, Xu WB, Schluter WW, Novak RT, et al. Preplanned Studies:
309 COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January
310 6, 2022–March 21, 2022. *China CDC Weekly* 2022; 4(14): 288-92.
311 <https://doi.org/10.46234/ccdcw2022.071>
- 312 15. National Health Commission of The People's Republic of China. Interim protocol of diagnosis and

- 313 treatment of 2019 novel coronavirus-associated pneumonia (the ninth version). Available from:
314 http://www.gov.cn/zhengce/zhengceku/2022-03/15/content_5679257.htm. [Accessed 22 April 2022].
- 315 16. World Health Organization. Living guidance for clinical management of COVID-19. Available at:
316 <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2>. [Accessed 22 April 2022].
- 317 17. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. Chinese Pediatric Novel Coronavirus Study
318 Team. SARS-CoV-2 Infection in Children. *N Engl J Med* 2020;382(17):1663-5.
319 <https://doi.org/10.1056/NEJMc2005073>
- 320 18. Cloete J, Kruger A, Masha M, du Plessis NM, Mawela D, Tshukudu M, et al. Paediatric
321 hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave
322 in South Africa: a multicentre observational study. *Lancet Child Adolesc Health* 2022;6(5):294-302.
323 [https://doi.org/10.1016/S2352-4642\(22\)00027-X](https://doi.org/10.1016/S2352-4642(22)00027-X)
- 324 19. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. Incidence Rates and Clinical
325 Outcomes of SARS-CoV-2 Infection with the Omicron and Delta Variants in Children Younger than
326 5 Years in the US. *JAMA Pediatr* 2022;1:e220945.
327 <https://doi.org/10.1001/jamapediatrics.2022.0945>
- 328 20. Iuliano AD, Brunkard JM, Boehmer TK, Peterson E, Adjei S, Binder AM, et al. Trends in Disease
329 Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous
330 SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022. *MMWR Morb*
331 *Mortal Wkly Rep* 2022;71(4):146-52. <https://doi.org/10.15585/mmwr.mm7104e4>
- 332 21. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom
333 prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2
334 during periods of omicron and delta variant dominance: a prospective observational study from the

- 335 ZOE COVID Study. *Lancet* 2022;7:S0140-6736(22)00327-0. <https://doi.org/10.1016/S0140->
- 336 6736(22)00327-0
- 337 22. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the
- 338 clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. *Lancet*
- 339 2022;399(10323):437-46. [https://doi.org/10.1016/S0140-6736\(22\)00017-4](https://doi.org/10.1016/S0140-6736(22)00017-4)
- 340 23. Peiris M, Cheng S, Mok CKP, Leung Y, Ng S, Chan K, et al. Neutralizing antibody titres to SARS-
- 341 CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with
- 342 mRNA BNT162b2 or inactivated CoronaVac vaccines. *Res Sq [Preprint]* 2022;rs.3.rs-1207071.
- 343 <https://doi.org/10.21203/rs.3.rs-1207071/v1>
- 344 24. Fowlkes AL, Yoon SK, Lutrick K, Gwynn L, Burns J, Grant L, et al. Effectiveness of 2-Dose
- 345 BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among
- 346 Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-
- 347 February 2022. *MMWR Morb Mortal Wkly Rep.* 2022 Mar 18;71(11):422-8.
- 348 <https://doi.org/10.15585/mmwr.mm7111e1>
- 349 25. Araos R, Jara A, Undurraga E, Zubizarreta J, Gonzalez C, Acevedo J, et al. Effectiveness of
- 350 CoronaVac in children 3 to 5 years during the omicron SARS-CoV-2 outbreak. *Research Square*
- 351 [Preprint]. <https://doi.org/10.21203/rs.3.rs-1440357/v1>
- 352 26. Roskosky M, Borah BF, DeJonge PM, Donovan CV, Blevins LZ, Lafferty AG, et al. Notes
- 353 from the Field: SARS-CoV-2 Omicron Variant Infection in 10 Persons Within 90 Days of Previous
- 354 SARS-CoV-2 Delta Variant Infection - Four States, October 2021-January 2022. *MMWR Morb*
- 355 *Mortal Wkly Rep* 2022;71(14):524-6. <https://doi.org/10.15585/mmwr.mm7114a2>
- 356 27. Jiehao C, Jin X, Daojiong L, Zhi Y, Lei X, Zhenghai Q, et al. A Case Series of Children With

- 357 2019 Novel Coronavirus Infection: Clinical and Epidemiological Features. *Clin Infect Dis*
358 2020;71(6):1547-51. <https://doi.org/10.1093/cid/ciaa198>
- 359 28. Wang X, Cai J, Yao W, Zhu Q, Zeng M. Socio-economic impact of influenza in children:a
360 single-centered hospital study in Shanghai. *Chin J Epidemiol* 2015;36(1):27-30.
- 361 29. Yonker LM, Boucau J, Regan J, Choudhary MC, Burns MD, Young N, et al. Virologic Features of
362 Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children. *J Infect Dis*
363 2021;224(11):1821-9. <https://doi.org/10.1093/infdis/jiab509>
- 364 30. Takahashi K, Ishikane M, Ujiie M, Iwamoto N, Okumura N, Sato T, et al. Duration of
365 Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees. *Emerg Infect Dis*
366 2022;28(5):998-1001. <https://doi.org/10.3201/eid2805.220197>
367

368 Table 1. Clinical characteristics of SARS-CoV-2 infection according to COVID-19 vaccination
 369 status

Vaccination status by age group (years)	Symptomatic case, n (%)	Relative risk (95% CI)	Febrile cases n (%)	Relative risk (95% CI)
0-17 (n=376)				
unvaccinated (n=250)	193 (77.2%)	ref	163 (65.2%)	ref
1 dose (n=16)	9 (56.3%)	0.73 (0.47-1.13)	7 (43.8%)	0.67 (0.38-1.18)
2 doses (n=110)	55 (50.0%)	0.65 (0.53-0.79)	46 (41.8%)	0.64 (0.51-0.81)
3-17 (n=272)				
unvaccinated (n=146)	103 (70.5%)	ref	86 (58.9%)	ref
1 dose (n=16)	9 (56.3%)	0.80 (0.51-1.24)	7 (43.8%)	0.74 (0.42-1.32)
2 doses (n=110)	55 (50.0%)	0.71(0.57-0.88)	46 (41.8%)	0.71 (0.55-0.92)

370 **Abbreviation:** ref = referent group.

371

372

Table 2. Clinical characteristics of SARS-CoV-2 virus infection by age group

Clinical characteristics	Total (n=376)	Age group (years)			<i>P</i> value	Vaccination status		<i>P</i> value
		<3	3-5	6-17		Unvaccinated	2-dose vaccination	
		(n=104)	(n=94)	(n=178)		(n=250)	(n=110)	
Asymptomatic cases, n (%)	119 (31.6%)	14 (13.5%)	29 (30.9%)	76 (42.7%)	0	57 (22.8%)	55 (50.0%)	0
Symptomatic cases, n (%)	257 (68.4%)	90 (86.5%)	65 (69.1%)	102 (57.3%)	0	193 (77.2%)	55 (50.0%)	0
Febrile cases, n (%)	216 (57.4%)	44 (42.3%)	59 (62.8%)	80 (44.9%)	0.006	163 (65.2%)	46 (41.8%)	0
Fever spike (°C), mean±SD	38.9±0.6	39.0±0.7	39.0±0.6	38.8±0.6	0.064	38.9±0.6	38.8±0.7	0.27
Fever duration (days), mean±SD	1.7±0.8	1.7±0.9	1.6±0.6	1.8±0.8	0.45	1.6±0.8	1.9±0.9	0.19




Figure 1. Daily COVID-19 cases referred to the designated hospital for children aged <18 years from March 1 to March 31, 2022




Figure 2. Model of epidemiological exposure over time among pediatric COVID-19 cases